Age-Dependent Differences in Canakinumab Safety: A Comprehensive Pharmacovigilance Analysis Using the FAERS Database.

Area of Science:

• Pharmacovigilance
• Immunology
• Oncology

Background:

• Canakinumab, an anti-interleukin-1β monoclonal antibody, has established efficacy but limited safety data across age groups.
• Postmarketing safety evaluation is essential for comprehensive understanding of drug risks.

Purpose of the Study:

• To evaluate the postmarketing safety profile of canakinumab using real-world adverse event data.
• To identify specific safety signals and age-related adverse event patterns associated with canakinumab therapy.

Main Methods:

• Analysis of adverse event (AE) reports from the FDA Adverse Event Reporting System (FAERS) database (2010 onwards).
• Disproportionality analysis using four algorithms (ROR, PRR, MGPS, BCNN) to detect safety signals.
• Weibull distribution modeling for temporal risk assessment of AEs.
• Age-stratified analysis to identify distinct AE profiles in different pediatric and adult populations.

Main Results:

• 9262 canakinumab-related AE reports were analyzed, revealing significant safety signals.
• Prominent signals included general disorders, administration site conditions, and infections/infestations.
• Distinct age-specific AE profiles: gastrointestinal/hepatobiliary disorders in children (<12 years), leukopenia in adolescents (12-17 years), and neoplasms in older adults (≥65 years).
• Temporal analysis indicated an early failure pattern, with approximately 40% of AEs occurring after one year of treatment.

Conclusions:

• Canakinumab is associated with significant safety signals, particularly infections and gastrointestinal/hepatobiliary disorders in younger patients, and neoplasms in elderly patients.
• The observed dual temporal pattern of AEs necessitates both short-term and long-term patient monitoring.
• Comprehensive pharmacovigilance strategies are required to ensure the safe use of canakinumab across all age demographics.